Age-specific occurrence of HPV16- and HPV18-related cervical cancer

Silvia De Sanjose, Cosette M. Wheeler, Wim G V Quint, William C. Hunt, Nancy E. Joste, Laia Alemany, F. Xavier Bosch, Evan R. Myers, Philip E. Castle

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The age-specific occurrence of cervical cancer related to human papillomavirus (HPV) genotypes HPV16 and HPV18, the two targeted by current HPV vaccines, is not well described. We therefore used data from two large, tissue-based HPV genotyping studies of cervical cancer, one conducted in New Mexico (n = 744) and an International study restricted to cancers (n = 1,729) from Europe, North America, and Australia to represent those regions with widely available cervical cancer screening facilities. HPV results were categorized as HPV16- or HPV18-positive (HPV16/18) versus other HPV genotype. We observed a decreasing proportion of HPV16/18-positive cancers with increasing age in the International study (Ptrend < 0.001) and New Mexico study (P trend < 0.001). There was no heterogeneity in the relationship between age of diagnosis and the proportion of HPV16/18-positive cancers between studies (P = 0.8). Combining results from the two studies (n = 2,473), the percentages of HPV16/18-positive cases were 77.0% [95% confidence interval (CI): 75.1%-78.9%] forwomenless than 65 years old and 62.7% [95% confidence interval (CI): 58.4%-66.9%] for women aged 65 and older (P < 0.001). In women who are under the age of 25 and have been vaccinated before becoming sexually active, the cervical cancer incidence is expected to be approximately 3.5 per million by 2020. HPV vaccination against HPV16/18 may have a greater impact on cervical cancers in women under 65 than in women aged 65 and older. These data will inform the age-specific impact of HPV vaccination and its integration with cervical cancer screening activities.

Original languageEnglish (US)
Pages (from-to)1313-1318
Number of pages6
JournalCancer Epidemiology Biomarkers and Prevention
Volume22
Issue number7
DOIs
StatePublished - Jul 2013
Externally publishedYes

Fingerprint

Uterine Cervical Neoplasms
Early Detection of Cancer
Vaccination
Genotype
Confidence Intervals
Papillomavirus Vaccines
Neoplasms
North America
Incidence

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

De Sanjose, S., Wheeler, C. M., Quint, W. G. V., Hunt, W. C., Joste, N. E., Alemany, L., ... Castle, P. E. (2013). Age-specific occurrence of HPV16- and HPV18-related cervical cancer. Cancer Epidemiology Biomarkers and Prevention, 22(7), 1313-1318. https://doi.org/10.1158/1055-9965.EPI-13-0053

Age-specific occurrence of HPV16- and HPV18-related cervical cancer. / De Sanjose, Silvia; Wheeler, Cosette M.; Quint, Wim G V; Hunt, William C.; Joste, Nancy E.; Alemany, Laia; Bosch, F. Xavier; Myers, Evan R.; Castle, Philip E.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 22, No. 7, 07.2013, p. 1313-1318.

Research output: Contribution to journalArticle

De Sanjose, S, Wheeler, CM, Quint, WGV, Hunt, WC, Joste, NE, Alemany, L, Bosch, FX, Myers, ER & Castle, PE 2013, 'Age-specific occurrence of HPV16- and HPV18-related cervical cancer', Cancer Epidemiology Biomarkers and Prevention, vol. 22, no. 7, pp. 1313-1318. https://doi.org/10.1158/1055-9965.EPI-13-0053
De Sanjose, Silvia ; Wheeler, Cosette M. ; Quint, Wim G V ; Hunt, William C. ; Joste, Nancy E. ; Alemany, Laia ; Bosch, F. Xavier ; Myers, Evan R. ; Castle, Philip E. / Age-specific occurrence of HPV16- and HPV18-related cervical cancer. In: Cancer Epidemiology Biomarkers and Prevention. 2013 ; Vol. 22, No. 7. pp. 1313-1318.
@article{8a87557e1b544024b8d5a609f6a8dd5c,
title = "Age-specific occurrence of HPV16- and HPV18-related cervical cancer",
abstract = "The age-specific occurrence of cervical cancer related to human papillomavirus (HPV) genotypes HPV16 and HPV18, the two targeted by current HPV vaccines, is not well described. We therefore used data from two large, tissue-based HPV genotyping studies of cervical cancer, one conducted in New Mexico (n = 744) and an International study restricted to cancers (n = 1,729) from Europe, North America, and Australia to represent those regions with widely available cervical cancer screening facilities. HPV results were categorized as HPV16- or HPV18-positive (HPV16/18) versus other HPV genotype. We observed a decreasing proportion of HPV16/18-positive cancers with increasing age in the International study (Ptrend < 0.001) and New Mexico study (P trend < 0.001). There was no heterogeneity in the relationship between age of diagnosis and the proportion of HPV16/18-positive cancers between studies (P = 0.8). Combining results from the two studies (n = 2,473), the percentages of HPV16/18-positive cases were 77.0{\%} [95{\%} confidence interval (CI): 75.1{\%}-78.9{\%}] forwomenless than 65 years old and 62.7{\%} [95{\%} confidence interval (CI): 58.4{\%}-66.9{\%}] for women aged 65 and older (P < 0.001). In women who are under the age of 25 and have been vaccinated before becoming sexually active, the cervical cancer incidence is expected to be approximately 3.5 per million by 2020. HPV vaccination against HPV16/18 may have a greater impact on cervical cancers in women under 65 than in women aged 65 and older. These data will inform the age-specific impact of HPV vaccination and its integration with cervical cancer screening activities.",
author = "{De Sanjose}, Silvia and Wheeler, {Cosette M.} and Quint, {Wim G V} and Hunt, {William C.} and Joste, {Nancy E.} and Laia Alemany and Bosch, {F. Xavier} and Myers, {Evan R.} and Castle, {Philip E.}",
year = "2013",
month = "7",
doi = "10.1158/1055-9965.EPI-13-0053",
language = "English (US)",
volume = "22",
pages = "1313--1318",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Age-specific occurrence of HPV16- and HPV18-related cervical cancer

AU - De Sanjose, Silvia

AU - Wheeler, Cosette M.

AU - Quint, Wim G V

AU - Hunt, William C.

AU - Joste, Nancy E.

AU - Alemany, Laia

AU - Bosch, F. Xavier

AU - Myers, Evan R.

AU - Castle, Philip E.

PY - 2013/7

Y1 - 2013/7

N2 - The age-specific occurrence of cervical cancer related to human papillomavirus (HPV) genotypes HPV16 and HPV18, the two targeted by current HPV vaccines, is not well described. We therefore used data from two large, tissue-based HPV genotyping studies of cervical cancer, one conducted in New Mexico (n = 744) and an International study restricted to cancers (n = 1,729) from Europe, North America, and Australia to represent those regions with widely available cervical cancer screening facilities. HPV results were categorized as HPV16- or HPV18-positive (HPV16/18) versus other HPV genotype. We observed a decreasing proportion of HPV16/18-positive cancers with increasing age in the International study (Ptrend < 0.001) and New Mexico study (P trend < 0.001). There was no heterogeneity in the relationship between age of diagnosis and the proportion of HPV16/18-positive cancers between studies (P = 0.8). Combining results from the two studies (n = 2,473), the percentages of HPV16/18-positive cases were 77.0% [95% confidence interval (CI): 75.1%-78.9%] forwomenless than 65 years old and 62.7% [95% confidence interval (CI): 58.4%-66.9%] for women aged 65 and older (P < 0.001). In women who are under the age of 25 and have been vaccinated before becoming sexually active, the cervical cancer incidence is expected to be approximately 3.5 per million by 2020. HPV vaccination against HPV16/18 may have a greater impact on cervical cancers in women under 65 than in women aged 65 and older. These data will inform the age-specific impact of HPV vaccination and its integration with cervical cancer screening activities.

AB - The age-specific occurrence of cervical cancer related to human papillomavirus (HPV) genotypes HPV16 and HPV18, the two targeted by current HPV vaccines, is not well described. We therefore used data from two large, tissue-based HPV genotyping studies of cervical cancer, one conducted in New Mexico (n = 744) and an International study restricted to cancers (n = 1,729) from Europe, North America, and Australia to represent those regions with widely available cervical cancer screening facilities. HPV results were categorized as HPV16- or HPV18-positive (HPV16/18) versus other HPV genotype. We observed a decreasing proportion of HPV16/18-positive cancers with increasing age in the International study (Ptrend < 0.001) and New Mexico study (P trend < 0.001). There was no heterogeneity in the relationship between age of diagnosis and the proportion of HPV16/18-positive cancers between studies (P = 0.8). Combining results from the two studies (n = 2,473), the percentages of HPV16/18-positive cases were 77.0% [95% confidence interval (CI): 75.1%-78.9%] forwomenless than 65 years old and 62.7% [95% confidence interval (CI): 58.4%-66.9%] for women aged 65 and older (P < 0.001). In women who are under the age of 25 and have been vaccinated before becoming sexually active, the cervical cancer incidence is expected to be approximately 3.5 per million by 2020. HPV vaccination against HPV16/18 may have a greater impact on cervical cancers in women under 65 than in women aged 65 and older. These data will inform the age-specific impact of HPV vaccination and its integration with cervical cancer screening activities.

UR - http://www.scopus.com/inward/record.url?scp=84880005136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880005136&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-13-0053

DO - 10.1158/1055-9965.EPI-13-0053

M3 - Article

C2 - 23632816

AN - SCOPUS:84880005136

VL - 22

SP - 1313

EP - 1318

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 7

ER -